Related Experiment Video

Updated: Mar 31, 2026

Prehospital Thrombolysis: A Manual from Berlin
05:52

Prehospital Thrombolysis: A Manual from Berlin

Published on: November 26, 2013

22.5K

Streptokinase-A Drug for Thrombolytic Therapy: A Patent Review

Adinarayana Kunamneni1, Ravi Durvasula

  • 1Center for Global Health, Department of Internal Medicine, University of New Mexico and New Mexico VA Health Care System, Albuquerque - 87108, New Mexico, USA. adikunamneni@rediffmail.com.

Recent Advances in Cardiovascular Drug Discovery
|October 27, 2015
PubMed

Insights

Streptokinase (SK), a cost-effective microbial enzyme, is a valuable agent for dissolving blood clots. This review details recent patents on SK, highlighting its properties for effective thrombolytic therapy.

Area of Science:

  • Biochemistry
  • Enzymology
  • Biotechnology

Background:

  • Fibrin accumulation in blood vessels causes thrombosis, leading to cardiovascular diseases like myocardial infarction.
  • Microbial enzymes offer a therapeutic approach to pathological fibrin accumulation.
  • Fibrinolytic enzymes, including streptokinase (SK), urokinase (UK), and tissue plasminogen activator (t-PA), are crucial for thrombolytic therapy.

Purpose of the Study:

  • To review recent patents concerning streptokinase (SK).
  • To summarize SK's occurrence, mechanism of action, and physico-chemical properties.
  • To cover SK's cloning, expression, production, structure, immunogenicity, modification, and clinical applications.

Main Methods:

  • Patent literature search and analysis.
  • Review of scientific publications on streptokinase.
  • Synthesis of information on SK's characteristics and therapeutic potential.

Main Results:

  • Streptokinase (SK) is identified as a cost-effective fibrinolytic enzyme, particularly suitable for low-resource settings.
  • Recent patents cover various aspects of SK, including its genetic engineering, production optimization, and clinical efficacy.
  • SK exhibits favorable properties for thrombolytic therapy, supported by extensive research and patent filings.

Conclusions:

  • Streptokinase (SK) is a preferred agent for thrombolytic therapy due to its efficacy and cost-effectiveness.
  • Ongoing patent activity reflects continued interest in optimizing SK production and application.
  • Further research and development based on patent insights can enhance SK's role in treating thrombotic conditions.

More Related Videos

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke09:21

Optimized Management of Endovascular Treatment for Acute Ischemic Stroke

Published on: January 18, 2018

12.8K
An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug07:50

An In vitro System to Gauge the Thrombolytic Efficacy of Histotripsy and a Lytic Drug

Published on: June 4, 2021

3.3K

Related Concept Videos

Venous Thrombosis III: Interprofessional Care01:29

Venous Thrombosis III: Interprofessional Care

Venous thrombosis requires effective prevention and treatment strategies to improve patient outcomes and reduce potential complications.Prevention StrategiesHealthcare providers must prioritize preventing venous thromboembolism (VTE) for all adult patients upon admission. Interventions depend on bleeding and thrombosis risk, medical history, current medications, diagnoses, planned procedures, and patient preferences. Patients on bed rest should change positions every two hours and, if not...
466
Clot Retraction and Fibrinolysis01:16

Clot Retraction and Fibrinolysis

After a fibrin clot is formed, the next step is clot retraction, a vital process facilitated by platelet contractile proteins, such as actin and myosin. These proteins pull the fibrin strands closer together and condense the clot. This action reduces the size of the clot, creating a smaller, denser structure that effectively seals off the damaged vessel. Clot retraction consolidates the clot and helps with wound healing by bringing the edges of the damaged blood vessel closer together.
10.2K
Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors01:20

Antiplatelet Drugs: Prostaglandin Synthesis, P2Y12 and Glycoprotein IIb/IIIa Inhibitors

Antiplatelet drugs emerge as frontline defenders against the insidious threat of thromboembolic diseases, where abnormal clots obstruct vital blood vessels. These drugs stand as bulwarks, inhibiting platelet aggregation and clot formation, thereby mitigating the risk of life-threatening conditions like myocardial infarction, coronary artery disease, and thrombotic strokes.
Prostaglandin synthesis inhibitors, exemplified by the widely known aspirin, wield their power by irreversibly acetylating...
1.5K
Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care01:29

Pulmonary Embolism II: Diagnostic Studies and Interprofessional Care

Diagnosing Pulmonary EmbolismDiagnosing pulmonary embolism (PE) involves clinical assessment and advanced imaging tests. The preferred diagnostic tool is the spiral (helical) CT scan or CT angiography (CTA), which uses intravenous contrast media to visualize the pulmonary vasculature and identify emboli.A ventilation-perfusion (V/Q) scan is an alternative for patients unable to receive contrast media. This scan includes both perfusion and ventilation scanning. Perfusion scanning involves...
661
Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions01:15

Impact of Pharmacokinetic–Pharmacodynamic Models: Regulatory Decisions

PK–PD modeling has significantly influenced FDA regulatory decisions, particularly drug approval, dosage optimization, and labeling. These models integrate pharmacokinetics (PK) and pharmacodynamics (PD) to predict drug behavior and effects, aiding in optimizing dosing regimens and enhancing the probability of clinical trial success.One notable example is Nesiritide (Natrecor®), a recombinant human brain natriuretic peptide for treating acute decompensated congestive heart failure...
72
Anticoagulant Drugs: Low-Molecular-Weight Heparins01:30

Anticoagulant Drugs: Low-Molecular-Weight Heparins

Hemostasis is a crucial process that prevents excessive blood loss from damaged blood vessels. It involves various mechanisms such as vasoconstriction, platelet adhesion and activation, and fibrin formation. The importance of each mechanism depends on the type of vessel injury. In contrast, thrombosis is the abnormal formation of a blood clot within the blood vessels, leading to potential complications if the clot obstructs blood flow. Thrombosis can be caused by increased coagulability of the...
2.4K